Skip to main content

Patient experience and quality of life during neoadjuvant therapy for pancreatic cancer: a systematic review and study protocol

Abstract

Purpose

Neoadjuvant therapy (NT) is increasingly being offered to patients with pancreatic ductal adenocarcinoma (PDAC) prior to surgical resection. However, the experience and quality of life (QOL) of patients undergoing NT are poorly understood.

Methods

A systematic review of the Cinahl, Embase, Medline, Pubmed, Scopus, and Web of Science databases was conducted to evaluate the available literature pertaining to the experience and QOL of patient’s undergoing NT for PDAC.

Results

Among 6041 articles screened, only six met criteria for full-text review including three prospective clinical trials of NT with QOL secondary endpoints. Overall, global QOL during or following NT did not significantly change from baseline. Pain scores seemed to improve during NT while the impact of NT on physical functioning varied across studies. No studies were identified evaluating other aspects of the patient experience.

Conclusion

Although NT appears to have a minor impact on the QOL of patients with PDAC, this systematic review identified significant evidence gaps in the literature. A protocol of a prospective observational cohort study utilizing a digital smartphone app that aims to evaluate the patient experience and longitudinal QOL of patients with PDAC undergoing NT is presented.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2

Data availability

N/A

References

  1. Siegel RL, Miller KD, Jemal A (2018) Cancer statistics. CA Cancer J Clin 68:7–30. https://doi.org/10.3322/caac.21442

    Article  PubMed  Google Scholar 

  2. Groot VP, Rezaee N, Wu W, Cameron JL, Fishman EK, Hruban RH, Weiss MJ, Zheng L, Wolfgang CL, He J (2017) Patterns, Timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma. Ann Surg 267:936–945. https://doi.org/10.1097/SLA.0000000000002234

    Article  Google Scholar 

  3. Cloyd J, Shen C, Santry H et al (2020) Disparities in the use of neoadjuvant therapy for resectable pancreatic ductal adenocarcinoma. J Natl Compr Cancer Netw 18(5):1–8

    Google Scholar 

  4. Bilimoria KY, Bentrem DJ, Ko CY, Tomlinson JS, Stewart AK, Winchester DP, Talamonti MS (2007) Multimodality therapy for pancreatic cancer in the U.S. : utilization, outcomes, and the effect of hospital volume. Cancer 110:1227–1234. https://doi.org/10.1002/cncr.22916

    Article  PubMed  Google Scholar 

  5. Altman AM, Wirth K, Marmor S, Lou E, Chang K, Hui JYC, Tuttle TM, Jensen EH, Denbo JW (2019) Completion of adjuvant chemotherapy after upfront surgical resection for pancreatic cancer is uncommon yet associated with improved survival. Ann Surg Oncol 26:4108–4116. https://doi.org/10.1245/s10434-019-07602-6

    Article  PubMed  Google Scholar 

  6. Tzeng C-WD, Tran Cao HS, Lee JE et al (2014) Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival. J Gastrointest Surg 18:16–24; discussion 24-25. https://doi.org/10.1007/s11605-013-2412-1

    Article  PubMed  Google Scholar 

  7. Cloyd JM, Katz MHG, Prakash L, Varadhachary GR, Wolff RA, Shroff RT, Javle M, Fogelman D, Overman M, Crane CH, Koay EJ, Das P, Krishnan S, Minsky BD, Lee JH, Bhutani MS, Weston B, Ross W, Bhosale P, Tamm EP, Wang H, Maitra A, Kim MP, Aloia TA, Vauthey JN, Fleming JB, Abbruzzese JL, Pisters PWT, Evans DB, Lee JE (2017) Preoperative therapy and pancreatoduodenectomy for pancreatic ductal adenocarcinoma: a 25-year single-institution experience. J Gastrointest Surg 21:164–174. https://doi.org/10.1007/s11605-016-3265-1

    Article  PubMed  Google Scholar 

  8. Mokdad AA, Minter RM, Zhu H, Augustine MM, Porembka MR, Wang SC, Yopp AC, Mansour JC, Choti MA, Polanco PM (2016) Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: a propensity score matched analysis. J Clin Oncol Off J Am Soc Clin Oncol 35:515–522. https://doi.org/10.1200/JCO.2016.68.5081

    Article  Google Scholar 

  9. Cloyd JM, Wang H, Egger ME, Tzeng CWD, Prakash LR, Maitra A, Varadhachary GR, Shroff R, Javle M, Fogelman D, Wolff RA, Overman MJ, Koay EJ, Das P, Herman JM, Kim MP, Vauthey JN, Aloia TA, Fleming JB, Lee JE, Katz MHG (2017) Association of clinical factors with a major pathologic response following preoperative therapy for pancreatic ductal adenocarcinoma. JAMA Surg 152:1048–1056. https://doi.org/10.1001/jamasurg.2017.2227

    Article  PubMed  PubMed Central  Google Scholar 

  10. Unno M, Hata T, Motoi F (2019) Long-term outcome following neoadjuvant therapy for resectable and borderline resectable pancreatic cancer compared to upfront surgery: a meta-analysis of comparative studies by intention-to-treat analysis. Surg Today 49:295–299. https://doi.org/10.1007/s00595-019-01786-w

    Article  PubMed  Google Scholar 

  11. Cloyd JM, Heh V, Pawlik TM, Ejaz A, Dillhoff M, Tsung A, Williams T, Abushahin L, Bridges JFP, Santry H (2020) Neoadjuvant therapy for resectable and borderline resectable pancreatic cancer: a meta-analysis of randomized controlled trials. J Clin Med:9. https://doi.org/10.3390/jcm9041129

  12. Cloyd JM, Tsung A, Hays J, Wills CE, Bridges JFP (2020) Neoadjuvant therapy for resectable pancreatic ductal adenocarcinoma: the need for patient-centered research. World J Gastroenterol 26:375–382. https://doi.org/10.3748/wjg.v26.i4.375

    Article  PubMed  PubMed Central  Google Scholar 

  13. Wells G, Shea B, O’Connell D, et al The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. Available www.ohri.ca/programs/clinical_epidemiology/oxford.htm

  14. Higgins JPT, Altman DG, Gøtzsche PC et al (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928. https://doi.org/10.1136/bmj.d5928

    Article  PubMed  PubMed Central  Google Scholar 

  15. Bingener-Casey J, Bauer BA, Cutshall SM et al (2019) The feasibility of individualized prehabilitation for patients undergoing gastrointestinal cancer resections: a pilot study. Minerva Chir 74:112–113. https://doi.org/10.23736/S0026-4733.18.07584-3

    Article  PubMed  Google Scholar 

  16. Heinrich S, Pestalozzi BC, Schäfer M, Weber A, Bauerfeind P, Knuth A, Clavien PA (2008) Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head. J Clin Oncol Off J Am Soc Clin Oncol 26:2526–2531. https://doi.org/10.1200/JCO.2007.15.5556

    CAS  Article  Google Scholar 

  17. Marker R, Peters J, Jankowski J (2018) Effects of preoperative exercise on physical fitness and body composition in pancreatic cancer survivors receiving neoadjuvant therapy: a case series. Rehabil Oncol 36:E1–E9

    Article  Google Scholar 

  18. Serrano PE, Herman JM, Griffith KA, Zalupski MM, Kim EJ, Bekaii-Saab TS, Ben-Josef E, Dawson LA, Ringash J, Wei AC (2014) Quality of life in a prospective, multicenter phase 2 trial of neoadjuvant full-dose gemcitabine, oxaliplatin, and radiation in patients with resectable or borderline resectable pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys 90:270–277. https://doi.org/10.1016/j.ijrobp.2014.05.053

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  19. Sato N, Motoi F, Iseki M, Kawaguchi K, Sato F, Katayose Y, Unno M (2019) Effect of neoadjuvant chemotherapy using gemcitabine and S1 before surgery for pancreatic cancer on quality of life. J Clin Oncol 37:e15719–e15719. https://doi.org/10.1200/JCO.2019.37.15_suppl.e15719

    Article  Google Scholar 

  20. Breen W, Jethwa KR, Yu NY, Miller RC, Ashman JB, Rule WG, Sio TTW, Mahipal A, Truty M, Neben-Wittich MA, Haddock MG, Hallemeier CL, Merrell KW (2019) Patient-reported quality of life during chemoradiation for intact pancreas cancer: a prospective registry study. Int J Radiat Oncol Biol Phys 105:E234–E235. https://doi.org/10.1016/j.ijrobp.2019.06.2005

    Article  Google Scholar 

  21. Viera AJ, Garrett JM (2005) Understanding interobserver agreement: the kappa statistic. Fam Med 37:360–363

    PubMed  Google Scholar 

  22. Belur J, Tompson L, Thornton A, Simon M (2018) Interrater reliability in systematic review methodology: exploring variation in coder decision-making. Sociol Methods Res:0049124118799372. https://doi.org/10.1177/0049124118799372

  23. van Dijk SM, Heerkens HD, Tseng DSJ, Intven M, Molenaar IQ, van Santvoort HC (2018) Systematic review on the impact of pancreatoduodenectomy on quality of life in patients with pancreatic cancer. HPB 20:204–215. https://doi.org/10.1016/j.hpb.2017.11.002

    Article  PubMed  Google Scholar 

  24. Macarulla T, Hendifar AE, Li C-P, Reni M, Riess H, Tempero MA, Dueck AC, Botteman MF, Deshpande CG, Lucas EJ, Oh DY (2020) Landscape of health-related quality of life in patients with early-stage pancreatic cancer receiving adjuvant or neoadjuvant chemotherapy: a systematic literature review. Pancreas 49:393–407. https://doi.org/10.1097/MPA.0000000000001507

    Article  PubMed  Google Scholar 

  25. Bottomley A, Aaronson NK, European Organisation for Research and Treatment of Cancer (2007) International perspective on health-related quality-of-life research in cancer clinical trials: the European Organisation for Research and Treatment of Cancer experience. J Clin Oncol Off J Am Soc Clin Oncol 25:5082–5086. https://doi.org/10.1200/JCO.2007.11.3183

    Article  Google Scholar 

  26. Bottomley A, Pe M, Sloan J, Basch E, Bonnetain F, Calvert M, Campbell A, Cleeland C, Cocks K, Collette L, Dueck AC, Devlin N, Flechtner HH, Gotay C, Greimel E, Griebsch I, Groenvold M, Hamel JF, King M, Kluetz PG, Koller M, Malone DC, Martinelli F, Mitchell SA, Moinpour CM, Musoro J, O'Connor D, Oliver K, Piault-Louis E, Piccart M, Pimentel FL, Quinten C, Reijneveld JC, Schürmann C, Smith AW, Soltys KM, Taphoorn MJB, Velikova G, Coens C, Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data (SISAQOL) consortium (2016) Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards. Lancet Oncol 17:e510–e514. https://doi.org/10.1016/S1470-2045(16)30510-1

    Article  PubMed  Google Scholar 

  27. Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Boige V, Bérille J, Conroy T (2013) Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol Off J Am Soc Clin Oncol 31:23–29. https://doi.org/10.1200/JCO.2012.44.4869

    CAS  Article  Google Scholar 

  28. Yalcin S, Dane F, Oksuzoglu B, Ozdemir NY, Isikdogan A, Ozkan M, Demirag GG, Coskun HS, Karabulut B, Evrensel T, Ustaoglu MA, Ozdemir F, Turna H, Yavuzsen T, Aykan F, Sevinc A, Akbulut H, Yuce D, Hayran M, Kilickap S (2020) Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine+nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study. BMC Cancer 20:259. https://doi.org/10.1186/s12885-020-06758-9

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  29. Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, Faluyi O, O'Reilly DA, Cunningham D, Wadsley J, Darby S, Meyer T, Gillmore R, Anthoney A, Lind P, Glimelius B, Falk S, Izbicki JR, Middleton GW, Cummins S, Ross PJ, Wasan H, McDonald A, Crosby T, Ma YT, Patel K, Sherriff D, Soomal R, Borg D, Sothi S, Hammel P, Hackert T, Jackson R, Büchler MW (2017) Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 389:1011–1024. https://doi.org/10.1016/S0140-6736(16)32409-6

    CAS  Article  PubMed  Google Scholar 

  30. Chan YM, Ng TY, Ngan HYS, Wong LC (2003) Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study. Gynecol Oncol 88:9–16. https://doi.org/10.1006/gyno.2002.6849

    CAS  Article  PubMed  Google Scholar 

  31. Fagotti A, Ferrandina G, Vizzielli G, Fanfani F, Gallotta V, Chiantera V, Costantini B, Margariti PA, Gueli Alletti S, Cosentino F, Tortorella L, Scambia G (2016) Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): final analysis of peri-operative outcome. Eur J Cancer 59:22–33. https://doi.org/10.1016/j.ejca.2016.01.017

    Article  PubMed  Google Scholar 

  32. Taira N, Iwata H, Hasegawa Y, Sakai T, Higaki K, Kihara K, Yamaguchi T, Ohsumi S, Shimozuma K, Ohashi Y (2014) Health-related quality of life and psychological distress during neoadjuvant endocrine therapy with letrozole to determine endocrine responsiveness in postmenopausal breast cancer. Breast Cancer Res Treat 145:155–164. https://doi.org/10.1007/s10549-014-2935-5

    CAS  Article  PubMed  Google Scholar 

  33. Blazeby JM, Sanford E, Falk SJ, Alderson D, Donovan JL (2005) Health-related quality of life during neoadjuvant treatment and surgery for localized esophageal carcinoma. Cancer 103:1791–1799. https://doi.org/10.1002/cncr.20980

    Article  PubMed  Google Scholar 

  34. Noordman BJ, Verdam MGE, Lagarde SM, Hulshof MCCM, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, van Laarhoven HWM, Nieuwenhuijzen GAP, Hospers GAP, Bonenkamp JJ, Cuesta MA, Blaisse RJB, Busch OR, ten Kate FJW, Creemers GJM, Punt CJA, Plukker JTM, Verheul HMW, Spillenaar Bilgen EJ, van Dekken H, van der Sangen MJC, Rozema T, Biermann K, Beukema JC, Piet AHM, van Rij CM, Reinders JG, Tilanus HW, Steyerberg EW, van der Gaast A, Sprangers MAG, van Lanschot JJB (2018) Effect of neoadjuvant chemoradiotherapy on health-related quality of life in esophageal or junctional cancer: results from the randomized CROSS trial. J Clin Oncol Off J Am Soc Clin Oncol 36:268–275. https://doi.org/10.1200/JCO.2017.73.7718

    CAS  Article  Google Scholar 

  35. Sclafani F, Peckitt C, Cunningham D, Tait D, Giralt J, Glimelius B, Keränen SR, Bateman A, Hickish T, Tabernero J, Thomas J, Brown G, Oates J, Chau I (2015) Short- and long-term quality of life and bowel function in patients with mri-defined, high-risk, locally advanced rectal cancer treated with an intensified neoadjuvant strategy in the randomized phase 2 EXPERT-C trial. Int J Radiat Oncol Biol Phys 93:303–312. https://doi.org/10.1016/j.ijrobp.2015.03.038

    Article  PubMed  Google Scholar 

  36. Miao Z-F, Liu X-Y, Wang Z-N, Zhao TT, Xu YY, Song YX, Huang JY, Xu H, Xu HM (2018) Effect of neoadjuvant chemotherapy in patients with gastric cancer: a PRISMA-compliant systematic review and meta-analysis. BMC Cancer 18:118. https://doi.org/10.1186/s12885-018-4027-0

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  37. Beaver K, Williamson S, Briggs J (2016) Exploring patient experiences of neo-adjuvant chemotherapy for breast cancer. Eur J Oncol Nurs 20:77–86. https://doi.org/10.1016/j.ejon.2015.06.001

    Article  PubMed  Google Scholar 

  38. Herman JM, Kitchen H, Degboe A, Aldhouse NVJ, Trigg A, Hodgin M, Narang A, Johnson CD (2019) Exploring the patient experience of locally advanced or metastatic pancreatic cancer to inform patient-reported outcomes assessment. Qual Life Res Int J Qual Life Asp Treat Care Rehab 28:2929–2939. https://doi.org/10.1007/s11136-019-02233-6

    Article  Google Scholar 

  39. Basch E, Deal AM, Dueck AC, Scher HI, Kris MG, Hudis C, Schrag D (2017) Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA 318:197–198. https://doi.org/10.1001/jama.2017.7156

    Article  PubMed  PubMed Central  Google Scholar 

  40. Kunneman M, Engelhardt EG, Ten Hove FLL et al (2016) Deciding about (neo-)adjuvant rectal and breast cancer treatment: Missed opportunities for shared decision making. Acta Oncol 55:134–139. https://doi.org/10.3109/0284186X.2015.1068447

    Article  PubMed  Google Scholar 

  41. Molinari M, El-Tawil K, Swaid F et al (2020) Patients’ treatment preferences for potentially resectable tumors of the head of the pancreas. HPB 22:265–274. https://doi.org/10.1016/j.hpb.2019.06.015

    Article  PubMed  Google Scholar 

  42. Heffernan N, Cella D, Webster K, Odom L, Martone M, Passik S, Bookbinder M, Fong Y, Jarnagin W, Blumgart L (2002) Measuring health-related quality of life in patients with hepatobiliary cancers: the functional assessment of cancer therapy-hepatobiliary questionnaire. J Clin Oncol Off J Am Soc Clin Oncol 20:2229–2239

    Article  Google Scholar 

  43. Eton DT, Yost KJ, Lai J-S, Ridgeway JL, Egginton JS, Rosedahl JK, Linzer M, Boehm DH, Thakur A, Poplau S, Odell L, Montori VM, May CR, Anderson RT (2017) Development and validation of the Patient Experience with Treatment and Self-management (PETS): a patient-reported measure of treatment burden. Qual Life Res Int J Qual Life Asp Treat Care Rehab 26:489–503. https://doi.org/10.1007/s11136-016-1397-0

    Article  Google Scholar 

  44. Young JM, Walsh J, Butow PN, Solomon MJ, Shaw J (2011) Measuring cancer care coordination: development and validation of a questionnaire for patients. BMC Cancer 11:298. https://doi.org/10.1186/1471-2407-11-298

    Article  PubMed  PubMed Central  Google Scholar 

  45. Adams JR, Ray D, Willmon R, Pulgar S, Dasari A (2019) Living with neuroendocrine tumors: assessment of quality of life through a mobile application. JCO Clin Cancer Inform 3:1–10. https://doi.org/10.1200/CCI.19.00025

    Article  PubMed  Google Scholar 

  46. Zarbin MA (2016) Challenges in applying the results of clinical trials to clinical practice. JAMA Ophthalmol 134:928–933. https://doi.org/10.1001/jamaophthalmol.2016.1266

    Article  PubMed  Google Scholar 

  47. Gorin SS, Haggstrom D, Han PKJ, Fairfield KM, Krebs P, Clauser SB (2017) Cancer care coordination: a systematic review and meta-analysis of over 30 years of empirical studies. Ann Behav Med 51:532–546. https://doi.org/10.1007/s12160-017-9876-2

    Article  PubMed  Google Scholar 

  48. Rosbach M, Andersen JS (2017) Patient-experienced burden of treatment in patients with multimorbidity—a systematic review of qualitative data. PLoS One 12:e0179916. https://doi.org/10.1371/journal.pone.0179916

    CAS  Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

The project described was partially supported by Award Number Grant UL1TR002733 from the National Center for Advancing Translational Sciences.

Author information

Authors and Affiliations

Authors

Contributions

All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by JC, SH, TH, and CM. The first draft of the manuscript was written by JC, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Jordan M. Cloyd.

Ethics declarations

Disclaimer

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Advancing Translational Sciences or the National Institutes of Health.

Conflicts of interest

The authors declare that they have no conflict of interest.

Code availability

N/A

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Cloyd, J.M., Hyman, S., Huwig, T. et al. Patient experience and quality of life during neoadjuvant therapy for pancreatic cancer: a systematic review and study protocol. Support Care Cancer 29, 3009–3016 (2021). https://doi.org/10.1007/s00520-020-05813-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-020-05813-2

Keywords

  • Psychological impact
  • Patient-reported outcomes
  • Supportive care
  • Pancreatic ductal adenocarcinoma
  • Palliative care
  • Patient preferences